Literature DB >> 32360274

Poorly differentiated thyroid carcinoma.

Bin Xu1, Ronald Ghossein2.   

Abstract

Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of follicular cell derived thyroid carcinoma with a prognosis intermediate between the indolent well differentiated thyroid carcinomas and the rapidly growing often fatal anaplastic carcinoma. While all investigators agree on the presence of this entity, there is disagreement in regard to its definition. In 2006, a set of criteria based solely on mitotic index ≥5/10 high power fields and/or tumor necrosis was proposed by a group of researchers from Memorial Sloan Kettering Cancer Center (MSKCC criteria) in New York. A year later, alternative diagnostic criteria of PDTC, so called the Turin proposal, were advocated by an international consensus group. The Turin proposal requires three criteria: 1) solid/trabecular/insular growth pattern; 2) absence of nuclear features of papillary carcinoma; and 3) at least one of the following three features: mitotic index ≥3/10 high power fields (HPFs), necrosis, or convoluted nuclei. In this review, we summarize the histology, diagnostic criteria (Turin proposal and MSKCC criteria) with their pros and cons, the prognostic factors, and molecular profile of PDTC, aiming to provide a practical and compreshensive review of this challenging entity.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; Insular carcinoma; Poorly differentiated thyroid carcinoma; RAS; Turin proposal

Year:  2020        PMID: 32360274     DOI: 10.1053/j.semdp.2020.03.003

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  8 in total

Review 1.  Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.

Authors:  Antonio Ieni; Roberto Vita; Cristina Pizzimenti; Salvatore Benvenga; Giovanni Tuccari
Journal:  J Pers Med       Date:  2021-04-23

Review 2.  Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?

Authors:  Marco Volante; Alfred K Lam; Mauro Papotti; Giovanni Tallini
Journal:  Endocr Pathol       Date:  2021-02-04       Impact factor: 3.943

Review 3.  Molecular Genetics of Follicular-Derived Thyroid Cancer.

Authors:  Elisabetta Macerola; Anello Marcello Poma; Paola Vignali; Alessio Basolo; Clara Ugolini; Liborio Torregrossa; Ferruccio Santini; Fulvio Basolo
Journal:  Cancers (Basel)       Date:  2021-03-07       Impact factor: 6.639

4.  Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study.

Authors:  Lei Xu; Qiong Zou; Ju Jiao; Yong Zhang
Journal:  Nucl Med Commun       Date:  2022-02-01       Impact factor: 1.690

5.  Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers.

Authors:  Hao Tan; Lidong Wang; Zhen Liu
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

Review 6.  [The value of molecular testing of thyroid aspirates].

Authors:  O Chijioke
Journal:  Pathologe       Date:  2022-01-10       Impact factor: 1.011

Review 7.  Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada.

Authors:  Mohannad Rajab; Richard J Payne; Véronique-Isabelle Forest; Marc Pusztaszeri
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

8.  PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.

Authors:  Soledad Cameselle-García; Sámer Abdulkader-Sande; María Sánchez-Ares; Gemma Rodríguez-Carnero; Jesús Garcia-Gómez; Francisco Gude-Sampedro; Ihab Abdulkader-Nallib; José Manuel Cameselle-Teijeiro
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.